User login
Rusty Crawford, RPh, was one of the authors of "Protocol to Evaluate Medication Nonadherence Among Patients with Metastatic Prostate Cancer," which was presented at the AVAHO 2014 Meeting in Portland, Oregon. The presentation discusses a new AVAHO-sponsored medication adherence protocol.
According to Crawford, the protocol will look at oral therapies and will help assess prescribing patterns and adherence rates to these new, oral medications.
"That's the big buzz in medicine these days," Crawford said. "Is oral better? It keeps outpatients at home but the downside of oral therapy is that it is not observed."
Rusty Crawford, RPh, was one of the authors of "Protocol to Evaluate Medication Nonadherence Among Patients with Metastatic Prostate Cancer," which was presented at the AVAHO 2014 Meeting in Portland, Oregon. The presentation discusses a new AVAHO-sponsored medication adherence protocol.
According to Crawford, the protocol will look at oral therapies and will help assess prescribing patterns and adherence rates to these new, oral medications.
"That's the big buzz in medicine these days," Crawford said. "Is oral better? It keeps outpatients at home but the downside of oral therapy is that it is not observed."
Rusty Crawford, RPh, was one of the authors of "Protocol to Evaluate Medication Nonadherence Among Patients with Metastatic Prostate Cancer," which was presented at the AVAHO 2014 Meeting in Portland, Oregon. The presentation discusses a new AVAHO-sponsored medication adherence protocol.
According to Crawford, the protocol will look at oral therapies and will help assess prescribing patterns and adherence rates to these new, oral medications.
"That's the big buzz in medicine these days," Crawford said. "Is oral better? It keeps outpatients at home but the downside of oral therapy is that it is not observed."
